National Affairs

Indian Intranasal Covid Vaccine To Be Launched On January  26

The first Indian intranasal Covid vaccine will be launched on 26 January. 

The company’s Chairman and Managing Director Krishna Ella said on Saturday that indigenous vaccine maker Bharat Biotech will launch the first intranasal Covid-19 vaccine of its kind in India on 26 January.

The company Chairman and Managing Director Krishna Ella said on Saturday that indigenous vaccine maker Bharat Biotech will launch the first intranasal Covid-19 vaccine of its kind in India on 26 January. 

Interacting with students at the India International Science Festival in Bhopal, Ella also informed that Lumpy-Provind, the domestic vaccine for lumpy dermatitis in cattle, is likely to be launched next month.

The Central Government had approved Bharat Biotech’s Nasal vaccine on 23 December 2022 amid increasing cases of corona virus worldwide. 

This vaccine can be used as a booster dose. Initially, the nasal vaccine will be available in private hospitals. 

The government has also included this vaccine in India’s Kovid 19 vaccination program. Earlier, the Drug Controller General of India, DCGI, had approved Bharat Biotech’s Intranasal Covid vaccine for emergency use

The Central Government had approved Bharat Biotech’s Nasal vaccine on 23 December 2022 amid increasing cases of corona virus worldwide. 

This vaccine can be used as a booster dose. Initially, the nasal vaccine will be available in private hospitals. 

The government has also included this vaccine in India’s Kovid 19 vaccination program. 

Earlier, the Drug Controller General of India, DCGI, had approved Bharat Biotech’s Intranasal Covid vaccine for emergency use.

This vaccine is given by spraying through the nose, which means that the vaccine is not applied on the arm of the person taking the vaccine. 

DCGI has approved intranasal covid vaccine for people above 18 years. The name of this vaccine of Bharat Biotech is BBV154.

Most of the viruses including corona enter the body through the mucosa. Mucosa is a sticky substance found in the nose, lungs, digestive system. 

The nasal vaccine produces an immune response directly in the mucosa, while the muscular vaccine is unable to do so. 

In an interview to India Today, Dr. Randeep Guleria, former director of AIIMS, had also told that the nasal vaccine is better because it is easier to apply and it creates immunity in the mucosa itself, which can prevent infection at the very beginning.

This vaccine will be administered only to people of 18 years or above. Vaccination is also going on for the children of 12 to 17 years, but they cannot get it done. 

The second thing is that it will be applied as a booster dose. Means, those who have got two doses done, only they can get this vaccine. However, it has also got the approval of the primary vaccine. 

That is, even if you have not taken any vaccine, you can get it installed. However, vaccination of almost the entire population has been done in India. But still a large population has not taken the booster dose.

 According to the Covin portal, more than 95.11 crore people have taken two doses in the country. But only 22 crore people have got booster dose.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top